|
Q-Med obtains approval for MACROLANETM VRF in Europe |
|
|
|
25 Sep 2007 |
MACROLANE VRF is a natural gel that is injected into the skin. The product is based on Q-Med's patented technology, NASHA, for the production of stabilized, non-animal hyaluronic acid. MACROLANE VRF can be used in body contouring both to give volume and to smooth out irregularities all over the body.
UPPSALA, Sweden | September 24, 2007 | MACROLANE VRF is a natural gel that is injected into the skin. The product is based on Q-Med's patented technology, NASHA, for the production of stabilized, non-animal hyaluronic acid. MACROLANE VRF can be used in body contouring both to give volume and to smooth out irregularities all over the body.
"Now there is a product that in a naturally way may recreate the body shapes that have been lost as a consequence of aging. MACROLANE VRF may refine and shape breast, decolletage, buttocks and other parts of the body according to the individual consumer's needs. Q-Med has conducted research and development for quite some time in this area and we feel very proud today" says Bengt Ågerup, CEO, Q-Med AB.
The first of Q-Med's products based on NASHA, RESTYLANE, was approved in Europe in 1996 and since then seven million treatments have been performed. MACROLANE VRF will be launched for plastic surgeons during 2007 and 2008.
Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA™ for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: RESTYLANE for the filling out of lips and facial wrinkles and for facial contouring, DUROLANE, for the treatment of osteoarthritis of the hip and knee joints, DEFLUX for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, ZUIDEX, for the treatment of stress urinary incontinence in women and SOLESTA, for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 600 co-workers, with approximately 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Large Cap segment of the OMX Nordic Exchange in Stockholm.
SOURCE: Q-Med |
